INTRODUCTION
Prostate cancer (PCa) is the most prevalent malignancy and second most lethal cancer in men in the United States. The incidence and mortality rates of PCa in African American (AA) men are the highest among all ethnic groups. 1 However, the genetic basis of this disease and the PCa disparities among the AA population remain largely unknown.
A recent study showed that speckle-type POZ protein (SPOP) is the most frequently mutated gene in PCa. 2 Barbieri et al. 2 performed exome sequencing on 112 prostate tumors predominantly of European descent and identified SPOP mutations at a frequency of 6%-15% across localized and advance prostate tumors. Other studies reported SPOP mutation frequencies of 4.4% (2 of 45), 3.4% (2 of 58), and 28.6% (2 of 7). [3] [4] [5] SPOP is a CULLIN3-dependent ubiquitin ligase responsible for the ubiquitination and proteolysis of steroid receptor coactivator-3 (SRC-3/AIB1), an oncogene overexpressed in many human cancers including PCa. [6] [7] [8] SPOP functions as a tumor suppressor in prostate cells by promoting the ubiquitination and proteasomal degradation of the SRC-3 protein and suppressing androgen receptor transcriptional activity. 9 The tumor suppressor effect of SPOP is abrogated by PCa-associated SPOP mutations. 9 Moreover, transfection of PCa cells with the most common SPOP mutant (the F133V variant) or SPOP small interfering ribonucleic acid showed increased tumor invasion. 2 Tumors with SPOP mutations were positively associated with deletion of CHD1, FOXO3, and PRDM, suggesting that loss of one and matched normal tissues were extracted from frozen tissues using the DNeasy Blood and Tissue kit (QIAGEN, Valencia, CA, USA) according to the manufacturers' protocol. Exon-specific products were polymerase chain reaction (PCR) amplified using exon-specific primers ( sense and 0.4 µmol l −1 antisense primer, and 0.5 units of AmpliTaq Gold DNA polymerase. PCR amplification was performed with a DNA Engine Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA). PCR amplicons were purified using exonuclease I (USB/Affymetrix, Santa Clara, CA, USA) and shrimp alkaline phosphatase (USB/Affymetrix), and submitted to direct Sanger sequencing using the forward and reverse PCR primers. Primer sets for the amplification and sequencing of exons 6 and 7 have previously been described. 2 Mutations were confirmed by bi-directional sequencing of a second independent amplified PCR product from the original genomic DNA template. All sequencing was performed at the LCRC Genomics Facility (New Orleans, LA, USA).
Real-time-polymerase chain reaction and restriction enzyme digest analysis of speckle-type POZ protein for structural variation determination Total ribonucleic acid (RNA) was extracted from frozen PCa tissue using TRIzol (Invitrogen, Carlsbad, CA, USA), according to the manufacturers' protocol. RNA was treated with deoxyribonuclease, and complementary DNA (cDNA) was generated with the SuperScript III First-Strand synthesis system (Invitrogen). The full-length SPOP cDNA was amplified using primers designed to amplify a product of approximately 1.25 kb that covers the entire coding region of SPOP: 5'-ACAGAAATCTTTGCCCCCTGAC-3' (forward) and 5'-GGTGGTCAGTGGCAGCAACAG-3' (reverse). The real-time PCR (RT-PCR) products were digested with PvuII (Promega, Madison, WI, USA) and analyzed on a 2% Tris-borate-EDTA agarose gel.
Real-time quantitative polymerase chain reaction analysis of speckle-type POZ protein expression
Quantitative real-time polymerase chain reaction was performed using the cDNA templates synthesized from RNA samples and a SPOP TaqMan probe purchased from Applied Biosystems (SPOP ID: HS00737433; Foster City, CA, USA). Briefly, 1 µl of cDNA was mixed in a total volume of 5 µl with 2× TaqMan Universal Master Mix (Applied Biosystems), 0.25 µl SPOP primer/probe mix, and 1.25 µl of water. The thermal cycling conditions were as follows: 2 min at 50°C, 10 min at 95°C, and 40 cycles at 95°C for 15 s followed by 60°C for 1 min. Data were collected and analyzed with a 7900 HT RT-PCR instrument (Applied Biosystems). SPOP gene expression levels were normalized to a calibrator (pool of tumor cDNAs) and the expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase. The comparative cycle threshold method ) was used to analyze relative gene expression differences between paired-set samples of normal tissue and AA-PCa tumor tissue.
Statistical analysis
Statistical analysis of the messenger RNA (mRNA) expression results was performed using Wilcoxon's signed rank test. Clinical variables, such as age and Gleason score, were compared using the chi-squared test. Statistical analyses were performed using GraphPad Prism6 (GraphPad Software, Inc., La Jolla, CA, USA), and P < 0.05 was considered as statistically significant.
RESULTS
We screened for somatic variants in exons six and seven of the SPOP gene in 49 AA prostate tumor tissues because all of the SPOP mutations previously reported were within these two exons. 2 Three somatic SPOP missense mutations were identified in exon six in five tumor tissues (10%), and one somatic variant was identified in one tumor sample (Figure 1 and Table 3 ). The c.A260G (p.Y87C) and c.T305C (p.F102S) mutations were recurrent, being identified in two different tumor samples, whereas the c.G332A (p.G111E) mutation and c.C318T synonymous variant (p. I106I) were detected once. Because none of the corresponding blood DNA samples showed evidence of mutations, it was concluded that the observed mutations arose somatically. No variants were detected in exon seven. We also screened for somatic variants in the remaining SPOP exons (1-5 and 8-12) and detected no variants. 
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To determine the molecular impact of the SPOP mutations on SPOP expression, we performed RT-quantitative PCR (RT-qPCR) analysis of the six AA prostate tumors carrying SPOP mutations or the novel coding variant. As shown in Figure 2a , SPOP mRNA expression was significantly reduced in all six of the AA-PCa tumors carrying SPOP mutations or the variant compared with their matched normal tissue (P = 0.0313), supporting the notion that SPOP functions as a tumor suppressor gene.
To determine the potential association between SPOP mutations and the aggressiveness of AA-PCa, we classified the 49 tumors into two groups: aggressive and less aggressive. Tumors from patients age 60 years and less with a Gleason score 7 or greater were classified as aggressive PCa, and those from patients age 60 and less with a Gleason score <7 or over age 60 regardless of Gleason score were classified as less aggressive PCa. We found that five of 27 aggressive tumors harbored SPOP mutations or the novel variant, while only one of 22 less aggressive tumors harbored a mutation (P < 0.05; Table 3 ).
DISCUSSION
This is the first study to identify SPOP somatic mutations in AA prostate tumors. We performed Sanger sequencing on DNA isolated from enriched tumor cells from snap-frozen prostate tissues and demonstrated that 10% (5/49) of localized AA prostate tumors harbored SPOP somatic mutations. The frequency of mutations identified in our AA prostate tumor cohort is comparable to the frequency of the 6%-15% reported for European prostate tumor cohorts. 2 Until date, more than 30 SPOP somatic mutations have been reported in cohorts of prostate tumors; 20 (65%) of these mutations were identified in exon seven, and 11 (35%) were found in exon six (Figure 3) . [2] [3] [4] Interestingly, two missense mutations (p.G111E and p.F102S) and the synonymous variant (p.I106I) have not been reported in other prostate tumors cohorts; thus, they represent novel somatic mutations in our AA-PCa tumors. Although the 102 codon mutations were detected in AA and European prostate tumors, the p.F102S mutation identified in the AA tumors is different from the p.F102C mutation detected in European tumors. Recently, it was demonstrated that mutations within exon six, for example p.Y87C and p.F102C, attenuated the binding of SCR-3 to SPOP and increased androgen receptor transcriptional activity. We speculate that several novel mutations identified in our AA-PCa cohort, for example p.G111E and p.F102, will have similar functional effects on SCR-3 binding and androgen receptor activity.
The different landscape of SPOP mutations in exons six and seven between AA and European tumors led us to consider the possibility that additional mutations may exist in other SPOP coding regions in AA tumors. Therefore, we amplified and sequenced the remaining exons (1-5 and 8-12) in all 49 tumor tissues. However, no additional somatic mutations or coding variants were identified. To exclude the possibility of insertion or deletion events in the SPOP gene, which may result in exon skipping, we amplified the entire SPOP mRNA from 39 tumors for which mRNA was available and performed PvuII digestion. We did not detect deletions/insertions or exon skipping (data not shown), which further strengthens our conclusion that our AA prostate tumor cohort only harbors SPOP mutations in exon six. 
